{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal COVI-MSC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 6,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 6,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04909892"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2a Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 \"Long Haul\" Pulmonary Compromise"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-PLH-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04905836"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-COV-202"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04909879"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Non-COVID-19 Acute Respiratory Distress Syndrome: A Phase 2 Study of the Efficacy and Safety of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-ARDS-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04992247"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 \"Long Haul\" Pulmonary Compromise"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-PLH-201BR"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04728698"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-COV-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04903327"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Sorrento Therapeutics, Inc."
                        ],
                        "OrgStudyId": [
                              "MSC-COV-201BR"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}